
    
      In order to be able to interpret the results on a homogeneous population, given that several
      molecules have marketing authorization for the management of macular edema following a CRVO,
      the therapeutic management will be standardized by the use of aflibercept for patients
      requiring intravitreal injection, aflibercept being the most widely referenced treatment
      currently used in the participating centers.
    
  